Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Myriad Will Acquire Rules-Based Medicine

by Michael McCoy
May 9, 2011 | A version of this story appeared in Volume 89, Issue 19

Myriad Genetics has agreed to acquire Rules-Based Medicine for $80 million in cash. Based in Salt Lake City, Myriad is a molecular diagnostics company that markets nine products for assessing a person’s risk of developing disease. Austin, Texas-based RBM, meanwhile, discovers novel biomarkers for drug industry partners using its multiplex immunoassay technology. Myriad says the purchase will add eight product candidates and expand its portfolio into new disease states.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.